Caplin Point arm raises $31m from Eight Roads, F-Prime Capital

Decheng Capital
An automated machine works on purification of potential hepatitis C virus drug candidate at the Gilead Sciences Inc. lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012. Photographer: David Paul Morris/Bloomberg

Caplin Steriles, the injectables subsidiary of Indian pharmaceutical firm Caplin Point Laboratories, has raised Rs 218 crore ($30.6 million) from Eight Roads Ventures, the proprietary investment arm of Fidelity International and its US-based sister fund, F-Prime Capital.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.